{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T23:04:19Z","timestamp":1784934259762,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Key Research & Development Program","award":["2020YFC2003904"],"award-info":[{"award-number":["2020YFC2003904"]}]},{"name":"Clinical Research Innovation Plan of Shanghai General Hospital","award":["CTCCR-2018B01"],"award-info":[{"award-number":["CTCCR-2018B01"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation","doi-asserted-by":"crossref","award":["81770953"],"award-info":[{"award-number":["81770953"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation","doi-asserted-by":"crossref","award":["82070992"],"award-info":[{"award-number":["82070992"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"intelligent medical project of Shanghai","award":["2018ZHYL0222"],"award-info":[{"award-number":["2018ZHYL0222"]}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["17411950204"],"award-info":[{"award-number":["17411950204"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81900900"],"award-info":[{"award-number":["81900900"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Translational Medicine Cross-Research Fund of Shanghai Jiao Tong University","award":["ZH2018QNA18"],"award-info":[{"award-number":["ZH2018QNA18"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The prevalence of myopia is increasing worldwide and is presently recognized as a major public health issue. Researchers and clinicians have been devoted in exploring appropriate clinical interventions to slow its progression in children. Mounting publications have proven that both orthokeratology (OK lens) and 0.01% atropine eyedrop can retard eye growth and myopia progression. However, it remains unclear whether the combination of OK lens and 0.01% atropine has the potential to magnify the effectiveness of myopia control. The present study aims to compare the myopia control efficiency of the combination of OK lens and 0.01% atropine with the monotherapy of OK lens in children.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The present study is a randomized, controlled, double-blind and multicenter clinical trial. A total of 96 children within 8\u201312\u2009years old were recruited. These participants are treated with the combination of OK lens and 0.01% atropine eyedrop or the combination of OK lens and placebo eyedrop. Each group includes 48 participants. The inclusion criteria are as follows: myopia between \u2212 1.00 and \u2212 4.00 D in either eye and astigmatism of no more than 1.50 D. The follow-up time points will be 1, 6, 12, 18, and 24\u2009months from randomization. The primary outcome is determined by the difference in axial length of the two groups, between the baseline and 24\u2009months from randomization.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The present randomized, controlled clinical trial would indicate the additive effects of the combination of OK lens and 0.01% atropine, and the extent of these effects, in retarding myopia progression and axial elongation in children.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Chinese Clinical Trial Registry (ChiCTR), <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/showproj.aspx?proj=29216\">ChiCTR1800018419<\/jats:ext-link>. Registered on 17 September 2018. <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/showproj.aspx?proj=29216\">http:\/\/www.chictr.org.cn\/showproj.aspx?proj=29216<\/jats:ext-link><\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-021-05825-1","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T11:03:12Z","timestamp":1638356592000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy of combined orthokeratology and 0.01% atropine for myopia control: the study protocol for a randomized, controlled, double-blind, and multicenter trial"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5393-3048","authenticated-orcid":false,"given":"Ying","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingru","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjie","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilian","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,1]]},"reference":[{"issue":"6","key":"5825_CR1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/cxo.12339","volume":"98","author":"BA Holden","year":"2015","unstructured":"Holden BA, Jong M, Davis S, Wilson D, Fricke T, Resnikoff S. Nearly 1 billion myopes at risk of myopia-related sight-threatening conditions by 2050 - time to act now. Clin Exper Optometry. 2015;98(6):491\u20133. https:\/\/doi.org\/10.1111\/cxo.12339.","journal-title":"Clin Exper Optometry"},{"issue":"6","key":"5825_CR2","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.ajo.2013.04.039","volume":"156","author":"BH Koffler","year":"2013","unstructured":"Koffler BH, Sears JJ. Myopia control in children through refractive therapy gas permeable contact lenses: is it for real? Am J Ophthalmol. 2013;156(6):1076\u201381 e1. https:\/\/doi.org\/10.1016\/j.ajo.2013.04.039.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"5825_CR3","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1167\/iovs.06-0562","volume":"48","author":"DO Mutti","year":"2007","unstructured":"Mutti DO, Hayes JR, Mitchell GL, Jones LA, Moeschberger ML, Cotter SA, et al. Refractive error, axial length, and relative peripheral refractive error before and after the onset of myopia. Invest Ophthalmol Vis Sci. 2007;48(6):2510\u20139. https:\/\/doi.org\/10.1167\/iovs.06-0562.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7543","key":"5825_CR4","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/519276a","volume":"519","author":"E Dolgin","year":"2015","unstructured":"Dolgin E. The myopia boom. Nature. 2015;519(7543):276\u20138. https:\/\/doi.org\/10.1038\/519276a.","journal-title":"Nature"},{"key":"5825_CR5","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1097\/IAE.0000000000001489","volume":"37","author":"Y Ikuno","year":"2017","unstructured":"Ikuno Y. Overview of the complications of high myopia. Retina (Philadelphia, Pa). 2017;37:2347\u201351.","journal-title":"Retina (Philadelphia, Pa)"},{"issue":"10","key":"5825_CR6","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/j.ophtha.2011.03.012","volume":"118","author":"MW Marcus","year":"2011","unstructured":"Marcus MW, de Vries MM, Junoy Montolio FG, Jansonius NM. Myopia as a risk factor for open-angle glaucoma: a systematic review and meta-analysis. Ophthalmology. 2011;118(10):1989\u201394 e2. https:\/\/doi.org\/10.1016\/j.ophtha.2011.03.012.","journal-title":"Ophthalmology"},{"issue":"11","key":"5825_CR7","doi-asserted-by":"publisher","first-page":"7077","DOI":"10.1167\/iovs.12-10565","volume":"53","author":"P Cho","year":"2012","unstructured":"Cho P, Cheung S-W. Retardation of myopia in Orthokeratology (ROMIO) study: a 2-year randomized clinical trial. Invest Ophthalmol Visual Sci. 2012;53(11):7077\u201385.","journal-title":"Invest Ophthalmol Visual Sci"},{"issue":"5","key":"5825_CR8","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1167\/iovs.10-5485","volume":"52","author":"T Kakita","year":"2011","unstructured":"Kakita T, Hiraoka T, Oshika T. Influence of overnight orthokeratology on axial elongation in childhood myopia. Invest Ophthalmol Visual Sci. 2011;52(5):2170\u20134. https:\/\/doi.org\/10.1167\/iovs.10-5485.","journal-title":"Invest Ophthalmol Visual Sci"},{"issue":"1","key":"5825_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/1471-2415-14-141","volume":"14","author":"MJ Zhu","year":"2014","unstructured":"Zhu MJ, Feng HY, He XG, Zou HD, Zhu JF. The control effect of orthokeratology on axial length elongation in Chinese children with myopia. BMC Ophthalmol. 2014;14(1):141. https:\/\/doi.org\/10.1186\/1471-2415-14-141.","journal-title":"BMC Ophthalmol"},{"key":"5825_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1089\/jop.1999.15.85","volume":"15","author":"YF Shih","year":"1999","unstructured":"Shih YF, Chen CH, Chou AC, Ho TC, Lin LL, Hung PT. Effects of different concentrations of atropine on controlling myopia in myopic children. J Ocul Pharmacol Ther. 1999;15:85\u201390.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"4","key":"5825_CR11","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ophtha.2015.11.010","volume":"123","author":"J Huang","year":"2016","unstructured":"Huang J, Wen D, Wang Q, McAlinden C, Flitcroft I, Chen H, et al. Efficacy comparison of 16 interventions for myopia control in children: a network meta-analysis. Ophthalmology. 2016;123(4):697\u2013708. https:\/\/doi.org\/10.1016\/j.ophtha.2015.11.010.","journal-title":"Ophthalmology"},{"issue":"3 Suppl","key":"5825_CR12","first-page":"281","volume":"15","author":"RH Kennedy","year":"2000","unstructured":"Kennedy RH, Dyer JA, Kennedy MA, Parulkar S, Kurland LT, Herman DC, et al. Reducing the progression of myopia with atropine: a long term cohort study of Olmsted County students. Binocul Vis Strabismus Q. 2000;15(3 Suppl):281\u2013304.","journal-title":"Binocul Vis Strabismus Q"},{"issue":"3","key":"5825_CR13","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.ophtha.2008.10.020","volume":"116","author":"L Tong","year":"2009","unstructured":"Tong L, Huang XL, Koh AL, Zhang X, Tan DT, Chua WH. Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine. Ophthalmology. 2009;116(3):572\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2008.10.020.","journal-title":"Ophthalmology"},{"issue":"8","key":"5825_CR14","doi-asserted-by":"publisher","first-page":"e1136","DOI":"10.1111\/aos.14166","volume":"97","author":"M Sacchi","year":"2019","unstructured":"Sacchi M, Serafino M, Villani E, Tagliabue E, Luccarelli S, Bonsignore F, et al. Efficacy of atropine 0.01% for the treatment of childhood myopia in European patients. Acta ophthalmologica. 2019;97(8):e1136\u2013e40. https:\/\/doi.org\/10.1111\/aos.14166.","journal-title":"Acta ophthalmologica"},{"issue":"11","key":"5825_CR15","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1001\/jamaophthalmol.2020.3820","volume":"138","author":"S Wei","year":"2020","unstructured":"Wei S, Li SM, An W, Du J, Liang X, Sun Y, et al. Safety and efficacy of low-dose atropine eyedrops for the treatment of myopia progression in Chinese children: a randomized clinical trial. JAMA Ophthalmol. 2020;138(11):1178\u201384. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.3820.","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"5825_CR16","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","volume":"119","author":"A Chia","year":"2012","unstructured":"Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology. 2012;119(2):347\u201354. https:\/\/doi.org\/10.1016\/j.ophtha.2011.07.031.","journal-title":"Ophthalmology"},{"issue":"1","key":"5825_CR17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","volume":"126","author":"JC Yam","year":"2019","unstructured":"Yam JC, Jiang Y, Tang SM, Law AKP, Chan JJ, Wong E, et al. Low-concentration atropine for myopia progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmology. 2019;126(1):113\u201324. https:\/\/doi.org\/10.1016\/j.ophtha.2018.05.029.","journal-title":"Ophthalmology"},{"issue":"8","key":"5825_CR18","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.1167\/iovs.12-9628","volume":"53","author":"Y Liu","year":"2012","unstructured":"Liu Y, Wildsoet C. The effective add inherent in 2-zone negative lenses inhibits eye growth in myopic young chicks. Invest Ophthalmol Vis Sci. 2012;53(8):5085\u201393. https:\/\/doi.org\/10.1167\/iovs.12-9628.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"9","key":"5825_CR19","doi-asserted-by":"publisher","first-page":"5827","DOI":"10.1167\/iovs.12-9943","volume":"53","author":"B Arumugam","year":"2012","unstructured":"Arumugam B, McBrien NA. Muscarinic antagonist control of myopia: evidence for M4 and M1 receptor-based pathways in the inhibition of experimentally-induced axial myopia in the tree shrewselective muscarinic antagonist control of myopia. Invest Ophthalmol Vis Sci. 2012;53(9):5827\u201337. https:\/\/doi.org\/10.1167\/iovs.12-9943.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"11","key":"5825_CR20","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1097\/OPX.0b013e31826c1831","volume":"89","author":"Z Chen","year":"2012","unstructured":"Chen Z, Niu L, Xue F, Qu X, Zhou Z, Zhou X, et al. Impact of pupil diameter on axial growth in orthokeratology. Optometry Vis Sci. 2012;89(11):1636\u201340. https:\/\/doi.org\/10.1097\/OPX.0b013e31826c1831.","journal-title":"Optometry Vis Sci"},{"issue":"2","key":"5825_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10633-019-09671-0","volume":"138","author":"LM Anders","year":"2019","unstructured":"Anders LM, Heinrich SP, Lagr\u00e8ze WA, Joachimsen L. Little effect of 0.01% atropine eye drops as used in myopia prevention on the pattern electroretinogram. Doc Ophthalmol. 2019;138(2):85\u201395. https:\/\/doi.org\/10.1007\/s10633-019-09671-0.","journal-title":"Doc Ophthalmol"},{"issue":"1","key":"5825_CR22","doi-asserted-by":"publisher","first-page":"12750","DOI":"10.1038\/s41598-020-69710-8","volume":"10","author":"N Kinoshita","year":"2020","unstructured":"Kinoshita N, Konno Y, Hamada N, Kanda Y, Shimmura-Tomita M, Kaburaki T, et al. Efficacy of combined orthokeratology and 0.01% atropine solution for slowing axial elongation in children with myopia: a 2-year randomised trial. Sci Rep. 2020;10(1):12750. https:\/\/doi.org\/10.1038\/s41598-020-69710-8.","journal-title":"Sci Rep"},{"issue":"6","key":"5825_CR23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1080\/02713683.2019.1568501","volume":"44","author":"Q Tan","year":"2019","unstructured":"Tan Q, Ng AL, Cheng GP, Woo VC, Cho P. Combined atropine with orthokeratology for myopia control: study design and preliminary results. Curr Eye Res. 2019;44(6):671\u20138. https:\/\/doi.org\/10.1080\/02713683.2019.1568501.","journal-title":"Curr Eye Res"},{"issue":"5","key":"5825_CR24","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s10384-018-0608-3","volume":"62","author":"N Kinoshita","year":"2018","unstructured":"Kinoshita N, Konno Y, Hamada N, Kanda Y, Shimmura-Tomita M, Kakehashi A. Additive effects of orthokeratology and atropine 0.01% ophthalmic solution in slowing axial elongation in children with myopia: first year results. Japanese J Ophthalmol. 2018;62(5):544\u201353. https:\/\/doi.org\/10.1007\/s10384-018-0608-3.","journal-title":"Japanese J Ophthalmol"},{"key":"5825_CR25","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1097\/OPX.0b013e31820f16fb","volume":"88","author":"P Kang","year":"2011","unstructured":"Kang P, Swarbrick H. Peripheral refraction in myopic children wearing orthokeratology and gas-permeable lenses. Optometry Vis Sci. 2011;88:476\u201382.","journal-title":"Optometry Vis Sci"},{"key":"5825_CR26","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1097\/OPX.0000000000000894","volume":"93","author":"Z Chen","year":"2016","unstructured":"Chen Z, Xue F, Zhou J, Qu X, Zhou X. Effects of orthokeratology on choroidal thickness and axial length. Optometry Vis Sci. 2016;93:1064\u201371.","journal-title":"Optometry Vis Sci"},{"issue":"9","key":"5825_CR27","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jfo.2020.04.023","volume":"43","author":"W Li","year":"2020","unstructured":"Li W, Jiang R, Zhu Y, Zhou J, Cui C. Effect of 0.01% atropine eye drops on choroidal thickness in myopic children. J Fr Ophtalmol. 2020;43(9):862\u20138.","journal-title":"J Fr Ophtalmol"},{"issue":"1","key":"5825_CR28","doi-asserted-by":"publisher","first-page":"18310","DOI":"10.1038\/s41598-020-75342-9","volume":"10","author":"ST Chiang","year":"2020","unstructured":"Chiang ST, Turnbull PRK, Phillips JR. Additive effect of atropine eye drops and short-term retinal defocus on choroidal thickness in children with myopia. Sci Rep. 2020;10(1):18310. https:\/\/doi.org\/10.1038\/s41598-020-75342-9.","journal-title":"Sci Rep"},{"key":"5825_CR29","doi-asserted-by":"crossref","unstructured":"Zhao W, Li Z, Hu Y, Jiang J, Long W, Cui D, et al. Short-term effects of atropine combined with orthokeratology (ACO) on choroidal thickness. Contact Lens Anterior Eye. 2021;44(3):101348.","DOI":"10.1016\/j.clae.2020.06.006"},{"key":"5825_CR30","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.clae.2018.10.026","volume":"42","author":"Z Chen","year":"2019","unstructured":"Chen Z, Huang S, Zhou J, Xiaomei Q, Zhou X, Xue F. Adjunctive effect of orthokeratology and low dose atropine on axial elongation in fast-progressing myopic children-a preliminary retrospective study. Contact Lens Anterior Eye. 2019;42:439\u201342.","journal-title":"Contact Lens Anterior Eye"},{"key":"5825_CR31","doi-asserted-by":"publisher","unstructured":"Wan L, Wei CC, Chen CS, Chang CY, Lin CJ, Chen JJ, et al. The synergistic effects of orthokeratology and atropine in slowing the progression of myopia. J Clin Med. 2018;7(9). https:\/\/doi.org\/10.3390\/jcm7090259.","DOI":"10.3390\/jcm7090259"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05825-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-021-05825-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05825-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T11:07:00Z","timestamp":1638356820000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-021-05825-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5825"],"URL":"https:\/\/doi.org\/10.1186\/s13063-021-05825-1","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"25 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Before the trial was initiated, this trial received ethical approval from the Institutional Review Board of Shanghai General Hospital (approval number: [2018]16, Additional file ). Each subcenter applied for local institutional review boards (IRBs) approval before participant recruitment. Any protocol modifications will be submitted to ethics committee. Written informed consent was collected from the participants (Additional file ) and their parents\/guardians (Additional file ) prior to the enrolment. Furthermore, this trial has been registered on the Chinese Clinical Trial Registry (identification number: ChiCTR1800018419)","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"863"}}